SECURITIES AND EXCHANGE COMMISSION

                            Washington, D.C. 20549

                                  FORM 8-K

                               CURRENT REPORT

                       Pursuant to Section 13 or 15(d)

                  of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 16, 1995

                                ImmunoGen, Inc.
              (Exact name of registrant as specified in its charter)

Massachusetts			                   0-17999	               04-2726691
(State or other jurisdiction	     	(Commission	           (IRS Employer
of incorporation)                  File Number)           Identification No.)


                128 Sidney Street, Cambridge, Massachusetts 02139

        Registrant's telephone number, including area code:(617) 661-9312



          




                               Page 1 of 5 pages








Item 5.  Other Events.

On August 17, 1995, the Registrant publicly disseminated a press release 
announcing that the Registrant issued $3.6 million of subordinated, 
convertible debentures pursuant to Regulation S of the Securities Act of 
1933.  The information contained in the press release is incorporated herein 
by reference and filed as Exhibit 99.1 hereto.


Item 7.    	Financial Statements and Exhibits.

(c)	Exhibits.

        99.1	The Registrant's Press Release dated August 17, 1995.

                           

































                                Page 2 of 5 pages

          



                                  SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the 
undersigned hereunto duly authorized.

                                                	ImmunoGen, Inc.
                                                 (Registrant)

Date:         August 29, 1995              		    /s/Frank J. Pocher        
                                                 Frank J. Pocher
                                                 Vice President and
                                                 principal financial officer














                                 Page 3 of 5 pages



























                                EXHIBIT INDEX

Exhibit                             		                     Sequential
Number		                 Description		                     Page Number

99.1                     The Registrant's Press                 5
                         Release dated August 17, 1995.

















                                 Page 4 of 5 pages

                              





























                                contact:     Mitchel Sayare
                                             Chairman, Chief Executive Officer
                                            	617-661-9312

      

                            FOR IMMEDIATE RELEASE

           IMMUNOGEN ISSUES $3.6 MILLION OF CONVERTIBLE DEBENTURES

Cambridge, Mass., August 17, 1995--ImmunoGen, Inc. (Nasdaq: IMGN) today  
announced that it has completed the sale of $3.6 million of subordinated, 
convertible debentures to a small number of European investors.  The 
transaction was undertaken pursuant to Regulation S of the Securities Act of 
1933.  

"This transaction provides timely financial support for the company," states 
Chairman and Chief Executive Officer, Mitchel Sayare.  "Since the 
registration of patients to our Phase III study of Oncolysin B has taken 
longer than we expected, these funds buy us more time to evaluate how to boost
the accrual rate. In addition we also are evaluating other options that could
shorten the time to complete the clinical trial, though we will need to raise
additional funds before these studies are completed."  

The terms of the transaction allow the investors to convert the debentures to
shares of ImmunoGen common stock during the period beginning October 2, 1995 
through July 31, 1996.  The conversion price is based on a pre-determined
discount to the market price at the time of conversion.

ImmunoGen, Inc. develops innovative biopharmaceuticals, primarily for the 
treatment of cancer.  The company has created potent immunoconjugates, 
consisting of toxins or drugs coupled to monoclonal antibodies for delivery to
and destruction of cancer cells at specific stages of disease.

                                     ###

 



                               Page 5 of 5 pages